Latest news
25 items- SECSEC Form 6-K filed by Orphazyme A/S6-K - Orphazyme A/S (0001764791) (Filer)
- SECSEC Form 20-F filed by Orphazyme A/S20-F - Orphazyme A/S (0001764791) (Filer)
- SECSEC Form 6-K filed by Orphazyme A/S6-K - Orphazyme A/S (0001764791) (Filer)
- SECSEC Form 6-K filed by Orphazyme A/S6-K - Orphazyme A/S (0001764791) (Filer)
- SECSEC Form 6-K filed by Orphazyme A/S6-K - Orphazyme A/S (0001764791) (Filer)
- SECSEC Form 6-K filed by Orphazyme A/S6-K - Orphazyme A/S (0001764791) (Filer)
- SECSEC Form NT 20-F/A filed by Orphazyme A/S (Amendment)NT 20-F/A - Orphazyme A/S (0001764791) (Filer)
- SECSEC Form 6-K filed by Orphazyme A/S6-K - Orphazyme A/S (0001764791) (Filer)
- SECSEC Form 6-K filed by Orphazyme A/S6-K - Orphazyme A/S (0001764791) (Filer)
- SECSEC Form NT 20-F filed by Orphazyme A/SNT 20-F - Orphazyme A/S (0001764791) (Filer)
- SECSEC Form 6-K filed by Orphazyme A/S6-K - Orphazyme A/S (0001764791) (Filer)
- SECSEC Form 6-K filed by Orphazyme A/S6-K - Orphazyme A/S (0001764791) (Filer)
- SECSEC Form 6-K filed by Orphazyme A/S6-K - Orphazyme A/S (0001764791) (Filer)
- SECSEC Form 6-K filed by Orphazyme A/S6-K - Orphazyme A/S (0001764791) (Filer)
- SECSEC Form 6-K filed by Orphazyme A/S6-K - Orphazyme A/S (0001764791) (Filer)
- NEWSOrphazyme Announced Notice Received from the Depositary to Holders of ADSs Regarding Termination of Deposit AgreementOrphazyme A/S in restructuring (ORPHA.CO) ("Orphazyme" or the "Company"), a late-stage biopharmaceutical company, has today received a notice from The Bank of New York Mellon, as depositary (the "Depositary"), that a notification has been sent to holders of American Depositary Shares ("ADSs") evidenced by American Depositary Receipts ("ADRs") representing deposited common shares of the Company, regarding termination of the Deposit Agreement dated September 28, 2020 among the Company, the Depositary, and Owners and ADR Holders (the "Deposit Agreement"). Owners and beneficial owners of the above ADRs ("ADR Holders") have on April 5, 2022 been notified by the Depositary that the Depositary wil
- SECSEC Form 6-K filed by Orphazyme A/S6-K - Orphazyme A/S (0001764791) (Filer)
- SECSEC Form 15-12B filed by Orphazyme A/S15-12B - Orphazyme A/S (0001764791) (Filer)
- SECSEC Form 6-K filed by Orphazyme A/S6-K - Orphazyme A/S (0001764791) (Filer)
- NEWSOrphazyme Reports An Enclosed Proposal For Statutory Restructuring Plan Will Be Submitted To Danish Maritime, Commercial High Court-Reuters
- SECSEC Form 6-K filed by Orphazyme A/S6-K - Orphazyme A/S (0001764791) (Filer)
- SECSEC Form EFFECT filed by Orphazyme A/SEFFECT - Orphazyme A/S (0001764791) (Filer)
- NEWSOrphazyme Withdraws European Application For Arimoclomol, Initiates Delisting Of Its ADSsOrphazyme A/S (NASDAQ:ORPH) has decided to withdraw its European Marketing Application for arimoclomol for Niemann-Pick disease Type C (NPC) ahead of a final vote and opinion by the CHMP scheduled for later this month. "Today's decision to withdraw the MAA enables us to consider the best possible path forward for arimoclomol," commented Orphazyme Chief Executive Officer Anders Vadsholt. The decision follows CHMP's negative trend vote on arimoclomol application following an Oral Explanation. Orphazyme is currently under an in-court restructuring and has reduced its workforce by approximately 50% to reduce costs. As part of the pursuit of a regulatory pathway in the U.S., the Company co
- NEWSThe Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage ReadoutHere's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Keytruda Monotherapy Approved For A Type Of Endometrial Cancer Merck & Co., Inc. (NYSE:MRK) said the U.S. Food and Drug Administration has approved its cancer immunotherapy as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, as determined by a FDA-approved test. These patients should have had disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. Merck shares were up 0.18% to $79.20 in premarket trading. Pfizer
- SECSEC Form 6-K filed by Orphazyme A/S6-K - Orphazyme A/S (0001764791) (Filer)
ORPH FAQ
6 questionsWhat does Orphazyme A/S do?
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The...Where does ORPH stock trade?
Orphazyme A/S (ORPH) is listed on NASDAQ.What sector and industry is ORPH in?
Orphazyme A/S operates in the Technology sector, Computer Software: Prepackaged Software industry.When did Orphazyme A/S go public?
Orphazyme A/S (ORPH) completed its IPO in 2020.What companies are similar to ORPH?
Notable peers in the same industry include MSFT (Microsoft Corporation), ORCL (Oracle Corporation), SAP (SAP SE), CRWD (CrowdStrike Holdings Inc.), CRM (Salesforce Inc.). Compare ORPH side-by-side with any of them on Quantisnow.How can I track ORPH on Quantisnow?
Quantisnow aggregates Orphazyme A/S's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ORPH to receive live email and push alerts on every new disclosure.